Clinical trials: Viral Load
Chronic Hepatitis B
Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment
The aim of interferon therapy in HBeAg negative chronic hepatitis B was to make patients obtain immune control to hepatitis B virus defined as sustained viral response after treatment.
- Trial name
- NCT02365402
- Testing
- Entecavir
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Beijing Ditan Hospital
HIV Infections
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
To determine the proportion of patients treated with amprenavir, zidovudine (ZDV), stavudine (D4T) and lamivudine (3TC) whose HIV-1 RNA level remains below the level of detection during 96 weeks of therapy.
- Trial name
- NCT00001095
- Testing
- Indinavir sulfate, Amprenavir, Nevirapine
- Where
- 12 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients
The purpose of this study is to compare 4 different combinations of anti-HIV drugs and to determine the number of people whose HIV blood levels decrease to 200 copies/ml or less while on the treatment.
- Trial name
- NCT00000912
- Testing
- Indinavir sulfate, Abacavir sulfate, Amprenavir
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 475 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Quantitative and Qualitative Research for "mHealth Program to Support People Living With HIV Across the HIV Care Continuum"
The goal of this randomized control trial (RCT) is to assess the effectiveness of Amp, a mobile health (mHealth) app designed to improve outcomes along the HIV care continuum for young Black men who have sex with men (YBMSM)…
- Trial name
- VSS (NCT06181916)
- Testing
- Amp
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sentient Research
HIV Infections
A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks
The purpose of this study is to compare different treatments for HIV infection to see which works best to lower HIV levels and to raise the number of CD4 cells (cells of the immune system that fight infection), in HIV-positive…
- Trial name
- NCT00000914
- Testing
- Indinavir sulfate, Ritonavir, Nelfinavir mesylate
- Where
- 15 sites in United States
- Volunteers
- 800 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Syphilis
Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)
This study proposes to investigate the performance of existing and new technologies for HIV diagnosis, one of the key strategies for Ending the HIV Epidemic in the U.S.
- Trial name
- EHPOC (NCT04793750)
- Testing
- Cepheid GeneXpert HIV-1 Qual POC HIV VL test, DPP HIV-Syphilis test system, OraQuick
- Where
- 3 sites in United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV Infections
A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials
Despite risk reduction counseling, some individuals in HIV vaccine trials or vaccine preparedness studies may engage in risk behavior that results in HIV infection.
- Trial name
- NCT00029913
- Testing
- Observation
- Where
- 21 sites in United States, Brazil and 2 more
- Volunteers
- 54 people
- Sponsor
- HIV Vaccine Trials Network
HIV Infections
Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination
The purpose of this study is to see if adding an HIV vaccine (ALVAC-HIV vCP1452), IL-2 (interleukin-2, a protein found in the blood that helps boost the immune system), or both to anti-HIV-drug therapy is safe, tolerable, and…
- Trial name
- NCT00006291
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Heavy Drinking
Gabapentin to Reduce Alcohol and Improve Viral Load Suppression
GRAIL is a Randomized Controlled Trial (RCT) among 300 HIV-positive persons with heavy alcohol consumption (by NIAAA definition) who have had detectable HIV viral load (HVL) at least 6 months after their HIV diagnosis.
- Trial name
- GRAIL (NCT05443555)
- Testing
- Gabapentin
- Where
- Uganda
- Volunteers
- 220 people
- Sponsor
- Boston Medical Center
HIV Infections
Outcomes of Anti-HIV Therapy During Early HIV Infection
The purpose of this study is to find out if it is effective to give aggressive anti-HIV therapy to patients who have been infected recently with HIV.
- Trial name
- NCT00001093
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen
Observational study to collect data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) despite switching from protease inhibitor to nonnucleoside reverse…
- Trial name
- NCT02191332
- Testing
- Viramune
- Volunteers
- 147 people
- Sponsor
- Boehringer Ingelheim
HIV Infections, Viral Load
Smart Linkage-to-HIV Care Via a Smartphone App
This randomized controlled trial evaluates the provision of individual patient laboratory results to newly diagnosed HIV positive smartphone users through a secure application (app) as a method to get them linked to and retained…
- Conditions
- HIV Infections, Viral Load, Patient Compliance, Antiretroviral Therapy
- Trial name
- SmartLtC (NCT02756949)
- Testing
- Smartphone application, Smartphone
- Where
- South Africa
- Volunteers
- 353 people
- Sponsor
- World Bank
HIV Infections, Pregnancy
A Study of HIV Levels During Pregnancy and After Childbirth
The purpose of this study is to find out if HIV-infected pregnant women taking anti-HIV drugs have an increased amount of HIV in their blood (viral load) after having the baby.
- Trial name
- NCT00041964
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 129 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV2 Infection
Washing COVID-19 Away With a Hypertonic Seawater Nasal Irrigation Solution
Nasal irrigations are thought to reduce the amount of virus from the nasal cavity. The aim of the present study is to evaluate the effect of a hypertonic seawater solution containing algal and herbal natural ingredients…
- Trial name
- NCT05729204
- Testing
- Hypertonic seawater solution
- Where
- Greece
- Volunteers
- 56 people
- Sponsor
- Larissa University Hospital
RNA Virus Infections, Viral Infection COVID-19
Effectiveness of Ammonium Chloride in Reducing Viral Load
This is a prospective, double-blind, randomized, comparative effectiveness pilot study evaluating the effect of a sustained-release ammonium chloride formulation (ACF) on viral load dynamics in adult patients with mild or…
- Conditions
- RNA Virus Infections, Viral Infection COVID-19, Influenza A and B
- Trial name
- ACTEarly (NCT07254052)
- Where
- 2 sites in Greece
- Volunteers
- 32 people
- Sponsor
- National and Kapodistrian University of Athens
Acute Respiratory Tract Infections, Pneumonia
Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infections
Respiratory syncytial virus (RSV) infection and bacterial co-infection are the most common causes of pneumonia. Currently, there is no vaccine available for RSV prevention, and the use of the antiviral medication ribavirin is not…
- Conditions
- Acute Respiratory Tract Infections, Pneumonia, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT05929599
- Testing
- 0.9% NaCl physiological saline, LiveSpo Navax
- Where
- Vietnam
- Volunteers
- 120 people
- Sponsor
- National Children's Hospital, Vietnam
HIV Infections
Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)
This is a 24 week placebo controlled, double-blind, 2-arm study of ADAPTAVIR, Monomeric Dala1-peptide T-amide (mDAPTA) compared to placebo, in HIV infected individuals with suppressed plasma viral loads < 200 copies/ml by highly…
- Trial name
- NCT00951743
- Testing
- Adaptavir (monomeric DAPTA)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Rapid Laboratories Inc.
HIV -1 Infection
Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life (2)
The goal of this clinical trial is to learn if subcutaneous ePGT121v1-LS and VRC07-523-LS added to standard antiretroviral therapy (ART) is safe and helps improve HIV viral suppression in infants living with HIV in Mozambique and…
- Trial name
- ENABLE 2 (NCT07655141)
- Testing
- Broadly neutralizing antibody (bNAb) ePGT121v1-LS, Saline (0.9% NaCl), Broadly neutralizing antibody (bNAb) VRC07-523-LS
- Volunteers
- 73 people
- Sponsor
- Hospital Universitario 12 de Octubre
HIV Infections
T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs
The purpose of this study is to show if a dose of T-20 added to an anti-HIV combination (chosen specifically for each patient) lowers viral load by at least a certain level after 24 weeks as compared to an anti-HIV combination…
- Trial name
- NCT00021554
- Testing
- Enfuvirtide
- Where
- 37 sites in Australia, Belgium and 7 more
- Volunteers
- 525 people
- Sponsor
- Hoffmann-La Roche
SARS-CoV-2 Infection, Influenza Viral Infections
Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study
The goal of this observational study is to learn about the influence of pre-existing mucosal immunity, i.e. antibodies and immune cells that are present at the nasal mucosa before infection, on the infectious viral load after…
- Conditions
- SARS-CoV-2 Infection, Influenza Viral Infections, Virus Shedding, Mucosal Immunity
- Trial name
- MIViral (NCT05794412)
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva